Evidence map›Paper›PMID 28919997›Full record

ArticleOncoimmunology

Increased infiltration and tolerised antigen-specific CD8

M Bahador, A Gras Navarro, M A Rahman, M Dominguez-Valentin, S Sarowar, E Ulvestad, G Njølstad, S A Lie, E K Kristoffersen, E Bratland and 1 more

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

M BahadorUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
A Gras NavarroUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
M A RahmanUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
M Dominguez-ValentinUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
S SarowarUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
E UlvestadUniversity of Bergen, Department of Clinical Science, Bergen, Norway.
G NjølstadHaukeland University Hospital, Department of Microbiology, Bergen, Norway.
S A LieUniversity of Bergen, Department of Clinical Dentistry, Bergen, Norway.
E K KristoffersenUniversity of Bergen, Department of Clinical Science, Bergen, Norway.
E BratlandUniversity of Bergen, Department of Clinical Science, Bergen, Norway.
M ChekenyaUniversity of Bergen, Department of Biomedicine, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) antigens in glioblastoma (GBM) present opportunities for personalised immunotherapy. However, their presence in GBM tissue is still under debate, and evidence of their impact on functional immune responses and prognosis is sparse. Here, we investigated the presence of pp65 (UL83) and immediate early 1 (IE-1) HCMV antigens in a cohort of Norwegian GBM patients (

Indexed as

GlioblastomaHCMVHLA-restricted T-cellsmemory T-cellsSurvival

Identifiers

PMID28919997
PMCPMC5593710
OpenAlexW2623781034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.